The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Warren Whitehead Biography and Net Worth

Director of Aptose Biosciences

Mr. Warren Whitehead is a Chartered Professional Accountant (CPA) and Certified Management Accountant (CMA) who has held multiple senior financial management positions in several biotechnology and pharmaceutical companies. Mr. Whitehead was the former Chairman and Board Member of Plantform Corporation and a former Board Member of Telesta Therapeutics (TSX), which was acquired by Prometic Life Sciences in 2016. He served as the Chief Financial Officer of ProMIS Neurosciences Inc. (formerly Amorfix Life Sciences Ltd.) from 2013 to 2015, a TSX-listed company targeting detection and effective treatment of Alzheimer’s disease and amyotrophic lateral sclerosis. Previously, from 2006 to 2008, he was the Chief Financial Officer of Arius Research Inc., a TSX-listed company developing anti-cancer antibodies, where he provided financial guidance and leadership during the acquisition of Arius by Roche in 2008. He was also the former Chief Financial Officer of Labopharm Inc. from 2000 to 2006, where he completed a series of public equity financings, including a cross-border Nasdaq offering. Other positions include Chief Financial Officer of Resolution Pharmaceuticals Inc., and a position in finance and business development at Glaxo Canada (now GlaxoSmithKline). Mr. Whitehead holds an MBA and BComm from the University of Windsor and a BA from the University of Western Ontario.

What is Warren Whitehead's net worth?: The estimated net worth of Warren Whitehead is at least $457.56 as of June 21st, 2021. Mr. Whitehead owns 1,640 shares of Aptose Biosciences stock worth more than $458 as of December 22nd. This net worth approximation does not reflect any other investments that Mr. Whitehead may own. Learn More about Warren Whitehead's net worth.
How do I contact Warren Whitehead?: The corporate mailing address for Mr. Whitehead and other Aptose Biosciences executives is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. Aptose Biosciences can also be reached via phone at 858-926-2730 and via email at [email protected]. Learn More on Warren Whitehead's contact information.
Has Warren Whitehead been buying or selling shares of Aptose Biosciences?: Warren Whitehead has not been actively trading shares of Aptose Biosciences during the last quarter. Most recently, Warren Whitehead sold 1,026 shares of the business's stock in a transaction on Monday, June 21st. The shares were sold at an average price of $50.25, for a transaction totalling $51,556.50. Following the completion of the sale, the director now directly owns 1,640 shares of the company's stock, valued at $82,410. Learn More on Warren Whitehead's trading history.
Who are Aptose Biosciences' active insiders?: Aptose Biosciences' insider roster includes Rafael Bejar (VP), Denis Burger (Director), Erich Platzer (Director), William Rice (CEO), Warren Whitehead (Director), and Donald Wilson, Jr. (Major Shareholder). Learn More on Aptose Biosciences' active insiders.
Are insiders buying or selling shares of Aptose Biosciences?: In the last twelve months, Aptose Biosciences insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $20,000.00. The most recent insider tranaction occured on November, 25th when CEO William G Rice bought 100,000 shares worth more than $20,000.00. Insiders at Aptose Biosciences own 3.9% of the company. Learn More about insider trades at Aptose Biosciences.
Information on this page was last updated on 11/25/2024.

Warren Whitehead Insider Trading History at Aptose Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/21/2021	Sell	1,026	$50.25	$51,556.50	1,640
12/22/2020	Sell	1,333	$60.90	$81,179.70	4,000
6/23/2020	Sell	1,200	$106.65	$127,980.00	3,416

Warren Whitehead Buying and Selling Activity at Aptose Biosciences

Aptose Biosciences Company Overview

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Today's Range

Now: $0.28

$0.21

$0.39

50 Day Range

MA: $0.30

$0.17

$0.40

2 Week Range

Now: $0.28

$0.13

$2.68

Volume

304,802,594 shs

Average Volume

1,745,122 shs

Market Capitalization

$16.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06

Vladimir Lenin was right…

From Porter & Company | Ad